Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank64
3Y CAGR-29.4%
5Y CAGR-16.5%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-29.4%/yr
vs +11.9%/yr prior
5Y CAGR
-16.5%/yr
Recent deceleration
Acceleration
-41.3pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 17.54% |
| 2024 | 48.99% |
| 2023 | -24.65% |
| 2022 | 49.74% |
| 2021 | -22.03% |
| 2020 | 43.28% |
| 2019 | 11.00% |
| 2018 | 31.69% |
| 2017 | 7.63% |
| 2016 | 9.20% |